We also could observe higher PD-L1 TPS in CDK7-overexpressing tumors, concluding that similar pathways might facilitate immune escape in HNSCC as well, and further supporting the statement that particularly patients with high CDK7 expression might profit from immunotherapy. The gene discussed is CDK7; the disease is head and neck squamous cell carcinoma.